Interleukin-13 and transforming growth factor β synergise in the pathogenesis of human intestinal fistulae

Gut

Volumn 62, Issue 1, 2013, Pages 63-72

  Scharl, Michael ^a,b   Frei, Sandra ^a   Pesch, Theresa ^a   Kellermeier, Silvia ^a   Arikkat, Joba ^a   Frei, Pascal ^a   Fried, Michael ^a,b   Weber, Achim ^a   Jehle, Ekkehard ^c   Rühl, Anne ^d   Rogler, Gerhard ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c Oberschwaben Klinik   (Germany)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA6 INTEGRIN; INTERLEUKIN 13; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 13 RECEPTOR ALPHA1; MESSENGER RNA; STAT6 PROTEIN; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE FISTULA; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SPHEROID CELL; WESTERN BLOTTING;

ADULT; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FIBROBLASTS; HT29 CELLS; HUMANS; INTEGRIN BETA CHAINS; INTERLEUKIN-13; INTESTINAL FISTULA; INTESTINAL MUCOSA; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84871153584     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-300498     Document Type: Article

References (34)

1. Solomon MJ. Fistulae and abscesses in symptomatic perianal Crohn's disease. Int J Colorectal Dis 1996;11:222-6. (Pubitemid 26382039)
2. Michelassi F, Stella M, Balestracci T, et al. Incidence, diagnosis, and treatment of enteric and colorectal fistulae in patients with Crohn's disease. Ann Surg 1993;218:660-6. (Pubitemid 23339120)
3. Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002;122:875-80. (Pubitemid 34267269)
4. Bourikas LA, Koutroubakis IE. Anti-TNF and fistulizing perianal Crohn's disease: use in clinical practice. Curr Drug Targets 2010;11:187-97.
5. Judge TA, Lichtenstein GR. Treatment of fistulizing Crohn's disease. Gastroenterol Clin North Am 2004;33:421-54, xi-xii. (Pubitemid 38737280)
6. Bataille F, Rohrmeier C, Bates R, et al. Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohn's disease. Inflamm Bowel Dis 2008;14:1514-27.
7. Scharl M, Weber A, Furst A, et al. Potential role for snail family transcription factors in the etiology of Crohn's disease-associated fistulae. Inflamm Bowel Dis 2011;17:1907-16.
8. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003;112:1776-84. (Pubitemid 38063698)
9. Arias AM. Epithelial mesenchymal interactions in cancer and development. Cell 2001;105:425-31. (Pubitemid 32520849)
10. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Biol 2006;7:131-42. (Pubitemid 43278296)
11. Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005;24:5764-74.
12. Kasai H, Allen JT, Mason RM, et al. TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res 2005;6:56.
13. Margetts PJ, Bonniaud P, Liu L, et al. Transient overexpression of TGF-{beta}1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol 2005;16:425-36. (Pubitemid 41725138)
14. Bates RC, Mercurio AM. Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol Biol Cell 2003;14:1790-800. (Pubitemid 36583533)
15. Peinado H, Quintanilla M, Cano A. Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. J Biol Chem 2003;278:21113-23. (Pubitemid 36806424)
16. Bates RC. Colorectal cancer progression: integrin alphavbeta6 and the epithelialmesenchymal transition (EMT). Cell Cycle 2005;4:1350-2. (Pubitemid 41437119)
17. Bates RC, Bellovin DI, Brown C, et al. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 2005;115:339-47. (Pubitemid 40385475)
18. Alves CC, Carneiro F, Hoefler H, et al. Role of the epithelial- mesenchymal transition regulator SLUG in primary human cancers. Front Biosci 2009;14:3035-50.
19. Wynn TA. IL-13 effector functions. Annu Rev Immunol 2003;21:425-56. (Pubitemid 37174537)
20. Donaldson DD, Whitters MJ, Fitz LJ, et al. The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1. J Immunol 1998;161:2317-24. (Pubitemid 28397044)
21. Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999;103:779-88. (Pubitemid 29152623)
22. Chiaramonte MG, Donaldson DD, Cheever AW, et al. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest 1999;104:777-85. (Pubitemid 29536363)
23. Lee CG, Homer RJ, Zhu Z, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 2001;194:809-21. (Pubitemid 32983016)
24. Kornmann M, Kleeff J, Debinski W, et al. Pancreatic cancer cells express interleukin-13 and -4 receptors, and their growth is inhibited by Pseudomonas exotoxin coupled to interleukin-13 and -4. Anticancer Res 1999;19:125-31. (Pubitemid 29168228)
25. Fujisawa T, Nakashima H, Nakajima A, et al. Targeting IL-13Ralpha2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine. Int J Cancer 2010;128:1221-31.
26. Vallera DA, Stish BJ, Shu Y, et al. Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model. Gut 2008;57:634-41. (Pubitemid 351579977)
27. Shimamura T, Fujisawa T, Husain SR, et al. Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy. Clin Cancer Res 2010;16:577-86.
28. Obiri NI, Husain SR, Debinski W, et al. Interleukin 13 inhibits growth of human renal cell carcinoma cells independently of the p140 interleukin 4 receptor chain. Clin Cancer Res 1996;2:1743-9. (Pubitemid 26356360)
29. Serve H, Oelmann E, Herweg A, et al. Inhibition of proliferation and clonal growth of human breast cancer cells by interleukin 13. Cancer Res 1996;56:3583-8. (Pubitemid 26251656)
30. Brenmoehl J, Miller SN, Hofmann C, et al. Transforming growth factor-beta 1 induces intestinal myofibroblast differentiation and modulates their migration. World J Gastroenterol 2009;15:1431-42.
31. Freije JM, Diez-Itza I, Balbin M, et al. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 1994;269:16766-73. (Pubitemid 24200439)
32. Hasegawa M, Fujimoto M, Kikuchi K, et al. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997;24:328-32. (Pubitemid 27104098)
33. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993;94:174-81. (Pubitemid 23308385)
34. Rieder F, Brenmoehl J, Leeb S, et al. Wound healing and fibrosis in intestinal disease. Gut 2007;56:130-9. (Pubitemid 46044899)